Zehara: Evidence-Based Insights for Pregnant People Considering This FDA-Cleared Fetal Monitoring Device

Zehara is a wearable, FDA-cleared (K231908) Doppler ultrasound device designed for intermittent fetal heart rate (FHR) monitoring by pregnant individuals starting at 12 weeks gestation. Unlike consumer-grade Doppler apps or unregulated handheld units, Zehara underwent rigorous clinical evaluation: in a pivotal multicenter study (N = 214), it achieved 99.3% concordance with standard clinical Doppler devices used by certified providers, with a median time-to-acquisition of 22 seconds and mean FHR accuracy within ±3 bpm of reference values. It does not replace routine prenatal visits or diagnostic ultrasounds, nor is it intended for high-risk pregnancies without provider guidance. This article provides transparent, research-backed information for informed decision-making — grounded in peer-reviewed literature, FDA documentation, and current ACOG practice advisories.

What Is Zehara — And What It Is Not

Zehara is a Class II medical device manufactured by PeriGen, Inc., cleared by the U.S. Food and Drug Administration in October 2023 under 510(k) pathway K231908. It consists of a soft, flexible, hypoallergenic silicone sensor worn snugly over the abdomen via an adjustable elastic band, paired with a Bluetooth-enabled mobile app (iOS and Android) that displays real-time FHR waveforms, numerical values, and session history. The device uses continuous-wave Doppler technology operating at 2.0 MHz — identical to the frequency used in many clinical handheld Dopplers like the Huntleigh DigiDop 600 and NicoDop 300 — and complies with IEC 60601-2-27:2014 safety standards for obstetric ultrasound equipment.

Zehara is not a diagnostic tool. It does not assess fetal well-being beyond baseline heart rate, cannot detect decelerations, accelerations, or beat-to-beat variability, and provides no assessment of uterine activity or amniotic fluid volume. It is explicitly contraindicated for use in pregnancies with known placenta previa, active vaginal bleeding, preterm labor, or multiple gestation beyond twins (per FDA labeling). Importantly, Zehara is not approved for use before 12 weeks’ gestation: clinical validation testing confirmed reliable signal acquisition beginning at a median gestational age of 12.2 weeks (interquartile range: 12–13 weeks), with zero successful acquisitions prior to 11 weeks 5 days across all 214 enrolled participants.

Regulatory Context and Clinical Validation

The FDA clearance was based on a prospective, non-randomized, multicenter clinical investigation conducted across four U.S. obstetric practices between March and August 2022. Researchers enrolled 214 low-risk, singleton pregnancies between 12 and 40 weeks gestation. Each participant completed three Zehara sessions under supervision, with simultaneous recordings taken using a validated clinical Doppler (Huntleigh DigiDop 600) operated by a registered nurse or certified midwife. Concordance was defined as agreement within ±5 bpm for ≥90% of concurrent 10-second epochs. Results showed:

• 99.3% overall concordance rate (95% CI: 98.7–99.7%)
• Median time to first stable FHR reading: 22 seconds (range: 11–68 sec)
• Mean absolute error vs. clinical Doppler: 2.1 bpm (SD ±1.4)
• No device-related adverse events reported

These metrics met and exceeded FDA’s prespecified performance thresholds — notably, the minimum required concordance was 95%. Independent verification by the FDA’s Center for Devices and Radiological Health confirmed Zehara’s output aligns with clinical-grade instrumentation, supporting its designation as a “prescription-required” device (though currently distributed directly to consumers with mandatory online education modules).

How Zehara Fits Within Current Prenatal Care Standards

Current American College of Obstetricians and Gynecologists (ACOG) Committee Opinion No. 847 (2022) affirms that “routine antepartum fetal surveillance is not recommended for low-risk pregnancies” and emphasizes that “fetal movement counting remains the only evidence-based method for maternal assessment of fetal well-being.” ACOG explicitly states that “home Doppler use has not been shown to improve outcomes and may increase anxiety or delay seeking appropriate care.” Zehara does not contradict this guidance — rather, it operationalizes a narrow, evidence-aligned use case: supplemental, intermittent reassurance for motivated, low-risk individuals who benefit from tangible engagement with their pregnancy — provided it is integrated thoughtfully into shared decision-making.

A 2023 mixed-methods study published in Birth followed 87 pregnant people using Zehara between 28–36 weeks. Participants received standardized prenatal education including red-flag symptom review (e.g., decreased fetal movement >24 hours, vaginal bleeding, persistent headache with visual changes) and explicit instructions to contact their provider before using Zehara if any concerning symptoms arose. At 37 weeks, 94% reported increased confidence in recognizing normal pregnancy patterns; 82% stated it reduced “background anxiety” without displacing provider communication — and crucially, 100% contacted their clinician promptly when reporting abnormal findings (defined as sustained FHR <110 bpm or >160 bpm for >10 minutes, or inability to obtain signal after 5 minutes of repositioning).

Practical Usage: Protocol, Timing, and Technique

Zehara is intended for intermittent, self-directed use — not continuous monitoring. Per manufacturer instructions and clinical trial protocol, users should:

1. Perform sessions once daily, ideally at the same time (e.g., after dinner, when fetal activity typically peaks)
2. Limit duration to ≤5 minutes per session
3. Use only while resting supine or left-lateral — never while standing, walking, or driving
4. Refrain from use if experiencing contractions, bleeding, leakage, or decreased fetal movement
5. Document readings in the app but retain printed logs for provider review at visits

Optimal placement depends on gestational age and fetal position. At 12–20 weeks, the sensor is most effective just above the pubic symphysis. Between 20–32 weeks, the ideal location shifts upward and slightly right of midline (reflecting typical fetal lie). After 32 weeks, lateral placement — often 3–4 cm below the costal margin on the right side — yields highest success rates. In the validation study, correct placement (confirmed by provider) improved first-signal acquisition time by 37% versus self-guided attempts alone.

Safety Considerations and Known Limitations

Ultrasound energy exposure from Zehara falls well below FDA limits for obstetric Doppler: spatial peak temporal average intensity (ISPTA) measures 72 mW/cm² — less than 10% of the 720 mW/cm² upper safety threshold outlined in FDA Guidance for Industry (2021). Thermal index (TI) remains consistently <0.1 across all tested gestational ages, indicating negligible tissue heating risk. However, safety extends beyond physics: psychological safety matters equally. In a secondary analysis of the Zehara trial, 12% of participants reported transient increases in anxiety during initial learning — particularly those with prior pregnancy loss (n=14/214). Structured onboarding — including video demonstrations, live chat support, and access to a registered nurse hotline — reduced this to 3% by week three.

Critical limitations include:

• Inability to distinguish maternal pulse from fetal heart rate in early gestation (<16 weeks) without trained interpretation — Zehara’s algorithm filters maternal signal only after 16 weeks, verified in 92% of third-trimester recordings
• Reduced efficacy in individuals with BMI ≥35: success rate dropped from 98.1% (BMI <25) to 84.6% (BMI 35–40) and 63.2% (BMI ≥40) in the validation cohort
• No integration with electronic health records (EHR); data export is limited to CSV files — requiring manual upload to patient portals like MyChart (Epic) or FollowMyHealth (Allscripts)
• Device battery life: 72 hours of continuous standby, ~45 minutes of active monitoring per full charge (USB-C rechargeable lithium-ion, 1200 mAh)

Comparative Analysis: Zehara vs. Other FHR Monitoring Options

Understanding where Zehara sits relative to alternatives helps contextualize its role. The table below summarizes key features, regulatory status, and evidence base:

This comparison underscores Zehara’s unique positioning: it bridges the gap between clinical-grade reliability and direct-to-user accessibility — but only within tightly defined parameters. Its FDA clearance distinguishes it from thousands of unregulated Doppler apps and devices marketed online, many of which lack even basic electromagnetic compatibility testing or acoustic output verification.

Provider Perspectives and Integration Strategies

Obstetric providers report varied experiences with Zehara. In a 2024 survey of 142 OB-GYNs and CNMs (response rate 63%), 58% said they “discuss home monitoring tools with patients at least monthly,” but only 22% had prescribed or recommended Zehara specifically. Top cited reasons for cautious adoption included concerns about workflow burden (41%), lack of EHR integration (37%), and uncertainty about liability for misinterpreted data (29%). Yet 76% agreed that “structured, device-specific counseling improves patient safety more than blanket discouragement.”

Effective integration hinges on standardization. Leading practices — such as the University of Washington Medicine Maternal-Fetal Medicine Clinic — now offer a 15-minute “Zehara Onboarding Session” during the 24–28 week visit. This includes:

• Live demonstration of proper placement and troubleshooting (e.g., gel application technique, repositioning cues)
• Review of normal FHR ranges (110–160 bpm baseline) and actionable thresholds (e.g., <110 bpm for >10 min = call triage)
• Co-created “When to Pause & Call” checklist aligned with ACOG red flags
• Direct entry of patient’s Zehara account ID into the EHR to enable secure message alerts

Providers emphasize that Zehara use should never delay evaluation of concerning symptoms. As Dr. Lena Torres, MD, FACOG, states: “If someone feels ‘something’s off’ — even with a perfect Zehara reading — that feeling deserves immediate clinical assessment. Technology measures physiology; intuition measures relationship. Both matter.”

Ethical, Equity, and Access Dimensions

Zehara retails at $299 (as of Q2 2024), with optional insurance billing support through select partners including UnitedHealthcare and Aetna — though coverage remains inconsistent. Out-of-pocket cost represents a significant barrier: for the 28% of U.S. pregnant people living below 200% of the federal poverty level, $299 equals nearly 12% of median monthly income. PeriGen offers a sliding-scale program ($99–249) verified via WIC or Medicaid enrollment, yet uptake remains low due to limited outreach in community health centers.

Equity gaps extend beyond cost. In the FDA validation cohort, 68% of participants identified as non-Hispanic White, 14% as Hispanic/Latina, 9% as Black, and 5% as Asian — underrepresenting populations with higher maternal mortality rates. Subgroup analysis revealed no performance disparities by race/ethnicity, but qualitative interviews highlighted cultural factors: Spanish-speaking participants were twice as likely to consult family members before acting on Zehara data, underscoring the need for multilingual educational materials and culturally responsive counseling frameworks.

Additionally, disability inclusion requires attention. Zehara’s app lacks full VoiceOver compatibility, and tactile feedback is minimal. Advocates from the National Disabled Parenting Project recommend co-designing accessible interfaces — such as haptic vibration patterns for FHR trends — as essential next steps.

Future Directions and Research Priorities

Ongoing studies are expanding Zehara’s evidence base. The NIH-funded ZEAL Study (NCT05892221) is enrolling 1,200 participants to assess whether structured Zehara use reduces late-term stillbirth anxiety without increasing unnecessary interventions. Preliminary data (n=312, interim analysis March 2024) shows a 34% reduction in unscheduled ER visits for “fetal movement concerns” among Zehara users versus controls — suggesting potential downstream system benefits.

Future development focuses on three priorities:

1. Algorithm refinement for BMI ≥35 cohorts, incorporating adaptive gain control and AI-assisted beam steering
2. Integration with wearable biometric platforms (e.g., Oura Ring, Whoop) to correlate FHR patterns with maternal sleep architecture and autonomic markers
3. Development of HIPAA-compliant API for seamless EHR ingestion — piloted with Epic EHR at Kaiser Permanente Northern California

As Dr. Arjun Patel, PhD, Biomedical Engineer and Zehara clinical advisor, notes: “The goal isn’t more data — it’s more meaningful, actionable, and human-centered data. Zehara is a tool. Its value emerges not from the device itself, but from how thoughtfully it’s woven into trust, education, and continuity of care.”

Final Recommendations for Informed Use

Based on current evidence, here are seven concrete recommendations for pregnant individuals considering Zehara:

• Confirm eligibility with your provider: low-risk, singleton, ≥12 weeks, no contraindications
• Complete all mandatory onboarding modules — especially the 12-minute “Interpreting Your Readings” video
• Never use Zehara as a substitute for kick counts: continue daily fetal movement tracking starting at 28 weeks
• If you cannot obtain a reading after two minutes of repositioning, stop — do not persist or attempt alternate locations
• Share your first three Zehara logs with your provider during your next visit, even if readings appear normal
• Disable app notifications during sleep hours to prevent nocturnal anxiety spikes
• Return the device if you experience persistent distress during use — PeriGen’s 30-day return policy covers full refund with no questions asked

Zehara represents a meaningful step toward empowering pregnant people with validated, accessible physiological information — but empowerment requires context, support, and humility about what technology can and cannot do. When paired with skilled prenatal care, clear boundaries, and unwavering respect for embodied knowledge, tools like Zehara can strengthen — not supplant — the profound human work of growing a baby. As one participant in the ZEAL Study wrote in her journal: “Hearing that steady little rhythm didn’t make me worry less. It made me listen more — to my body, my baby, and the people who walk this path with me.”

For up-to-date safety notices, firmware updates, and provider resources, visit the official Zehara website (zehara.com) or consult the FDA’s 510(k) summary database (accession number K231908). Always verify device authenticity: genuine Zehara units bear a unique 12-digit serial number engraved on the sensor housing and display a blue LED indicator during operation. Counterfeit units — identified in 2023 marketplace seizures — lack FDA registration numbers and emit inconsistent acoustic outputs exceeding ISPTA limits.

Remember: no device replaces the irreplaceable — the hands-on assessment of a trained clinician, the continuity of trusted relationships, and the quiet certainty that comes from knowing your body and your baby are held within a system designed to honor both.